Global Atherosclerosis Drugs Market Report 2023: Forecast Market Size, Growth Rate And Key Drivers

3 Nov, 2023

The global atherosclerosis drugs market is expected to grow from $46.8 billion in 2022 to $48.72 billion in 2023 at a compound annual growth rate (CAGR) of 3.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The atherosclerosis drugs market is expected to reach $54.89 billion in 2027 at a CAGR of 3%.

Global Atherosclerosis Drugs Market Key Driver

The prevalence of cardiovascular diseases is expected to drive the growth of the atherosclerosis drug market in the future. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels, with atherosclerosis referring to the accumulation of fats, cholesterol, and other substances on artery walls. Atherosclerosis is characterized by plaque buildup inside the arteries, leading to cardiovascular diseases like coronary heart disease and stroke. Atherosclerosis drugs are employed to treat cardiovascular conditions by reducing the risk of complications and managing underlying factors such as elevated cholesterol levels and blood clot formation.

Get a sample of the global atherosclerosis drugs market report

Global Atherosclerosis Drugs Market Segments

The global atherosclerosis drugs market is segmented:
1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Geography: The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global atherosclerosis drugs market.

Major Atherosclerosis Drugs Industry Players

  • Johnson And Johnson Private Limited
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bayer AG
  • Janssen Pharmaceuticals Inc.
  • Novartis AG
  • Merck And Co. Inc.
  • Sanofi S.A.
  • AstraZeneca plc
  • Get the full global atherosclerosis drugs market report

    Atherosclerosis Drugs Market Overview

    Atherosclerosis drugs refer to medications used to manage and treat atherosclerosis, a condition characterized by the buildup of plaque in the arteries. The goals of atherosclerosis drug treatment are to reduce plaque formation, slow its progression, and manage risk factors that contribute to atherosclerosis.

    Atherosclerosis Drugs Global Market Report 2023 provides data on the global atherosclerosis drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The atherosclerosis drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.